Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Erstveröffentlichung

2013

Authors

Kampa-Schittenhelm, Kerstin Maria

Heinrich, Michael Charles

Akmut, Figen

Döhner, Hartmut

Doehner, Konstanze

et al.

Wissenschaftlicher Artikel

Published in

Molecular cancer ; 12 (2013). - Art.-Nr. 19. - ISSN 1476-4598

Link to publication

https://dx.doi.org/10.1186/1476-4598-12-19

Institutions

UKU. Klinik für Innere Medizin III

Subject headings

[Free subject headings]: AC220 | Quizartinib | Leukemia | KIT | FLT3 | PDGFR | acute myeloid-leukemia | gastrointestinal stromal tumor | internal tandem duplications | ligand-independent activation | mast-cell leukemia | c-kit | myelodysplastic syndrome | flt3 gene | wild-type | systemic mastocytosis
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record